Home LiteratureArticle Details
PMID: 19040974 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Recent advances in molecular biology of thyroid cancer and their clinical implications.

Otolaryngologic clinics of North America ·Vol. 41 ·No. 6 ·2008-12-00 ·Pages 1135-46, ix

Xing M

Abstract

Thyroid cancer is the most common endocrine malignancy. With a rapidly rising incidence in recent years, novel efficient management strategies are increasingly needed for this cancer. Remarkable advances have occurred in understanding several major biologic areas of thyroid cancer, including the molecular alterations for the loss of radioiodine avidity of thyroid cancer, the pathogenic role of the MAP kinase and PI3K/Akt pathways and their related genetic alterations, and the aberrant methylation of functionally important genes in thyroid tumorigenesis and pathogenesis. These exciting advances provide unprecedented opportunities for the development of molecular-based novel diagnostic, prognostic, and therapeutic strategies for thyroid cancer.

MeSH Terms
DNA Methylation/physiology Gene Expression Regulation, Neoplastic Humans Methylation Mitogen-Activated Protein Kinases/genetics Oncogene Protein v-akt/genetics Proto-Oncogene Proteins B-raf/genetics Signal Transduction/physiology Thyroid Neoplasms/genetics,metabolism
Chemicals
BRAF protein, human Oncogene Protein v-akt Proto-Oncogene Proteins B-raf Mitogen-Activated Protein Kinases
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Xing Mingzhao
Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. mxing1@jhmi.edu
References (71)
71 references, click to expand
  1. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Endocr Rev. 2007 Dec;28(7):742-62 PMID: 17940185
  2. The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
    Nat Rev Cancer. 2002 Jul;2(7):489-501 PMID: 12094235
  3. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Endocrinology. 2007 Mar;148(3):936-41 PMID: 16946010
  4. TSH receptor status of thyroid neoplasms--TaqMan RT-PCR analysis of archival material.
    J Pathol. 1999 May;188(1):87-92 PMID: 10398146
  5. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
    Cancer. 2008 Nov 1;113(9):2440-7 PMID: 18831514
  6. Mutation of the PIK3CA oncogene in human cancers.
    Br J Cancer. 2006 Feb 27;94(4):455-9 PMID: 16449998
  7. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
    J Clin Invest. 2005 Jan;115(1):94-101 PMID: 15630448
  8. Quantitative assessment of promoter methylation profiles in thyroid neoplasms.
    J Clin Endocrinol Metab. 2005 Jul;90(7):4011-8 PMID: 15840741
  9. Overexpression and overactivation of Akt in thyroid carcinoma.
    Cancer Res. 2001 Aug 15;61(16):6105-11 PMID: 11507060
  10. The biology and clinical relevance of the PTEN tumor suppressor pathway.
    J Clin Oncol. 2004 Jul 15;22(14):2954-63 PMID: 15254063
  11. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis.
    Clin Endocrinol (Oxf). 2005 Apr;62(4):509-11 PMID: 15807885
  12. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    J Clin Endocrinol Metab. 2007 Dec;92(12):4686-95 PMID: 17911174
  13. Targeting the ERK signaling pathway in cancer therapy.
    Ann Med. 2006;38(3):200-11 PMID: 16720434
  14. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Cancer. 2008 Jul 15;113(2):247-55 PMID: 18470905
  15. Iodide handling by the thyroid epithelial cell.
    Exp Clin Endocrinol Diabetes. 2001;109(1):13-7 PMID: 11573132
  16. Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer.
    Cell Cycle. 2006 Sep;5(17):2036-9 PMID: 16931913
  17. Management of undifferentiated thyroid cancer.
    Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Dec;14(4):615-29 PMID: 11289738
  18. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Endocr Relat Cancer. 2008 Jun;15(2):511-20 PMID: 18509003
  19. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.
    Thyroid. 2006 Jul;16(7):633-42 PMID: 16889486
  20. Anaplastic thyroid carcinoma: an overview.
    Curr Oncol Rep. 2007 Mar;9(2):152-8 PMID: 17288883
  21. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
    J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93 PMID: 15928251
  22. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
    Endocr Relat Cancer. 2006 Mar;13(1):257-69 PMID: 16601293
  23. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Clin Cancer Res. 2007 Feb 15;13(4):1341-9 PMID: 17317846
  24. Increasing incidence of thyroid cancer in the United States, 1973-2002.
    JAMA. 2006 May 10;295(18):2164-7 PMID: 16684987
  25. Raf proteins and cancer: B-Raf is identified as a mutational target.
    Biochim Biophys Acta. 2003 Jun 5;1653(1):25-40 PMID: 12781369
  26. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer.
    J Clin Endocrinol Metab. 2006 Jan;91(1):98-104 PMID: 16263813
  27. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
    J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34 PMID: 10487692
  28. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.
    Cancer Res. 2004 Mar 1;64(5):1664-8 PMID: 14996725
  29. Guilty as charged: B-RAF is a human oncogene.
    Cancer Cell. 2004 Oct;6(4):313-9 PMID: 15488754
  30. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.
    Clin Endocrinol (Oxf). 2008 Jan;68(1):108-16 PMID: 17854396
  31. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.
    J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 PMID: 12788883
  32. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
    Cancer Res. 2005 Nov 15;65(22):10199-207 PMID: 16288007
  33. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
    Clin Endocrinol (Oxf). 2005 Sep;63(3):263-6 PMID: 16117812
  34. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16 PMID: 18492751
  35. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
    Cancer Biol Ther. 2006 Jul;5(7):779-85 PMID: 16721043
  36. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
    Eur J Endocrinol. 2006 Nov;155(5):645-53 PMID: 17062879
  37. High frequency of mutations of the PIK3CA gene in human cancers.
    Science. 2004 Apr 23;304(5670):554 PMID: 15016963
  38. Mutations of the BRAF gene in human cancer.
    Nature. 2002 Jun 27;417(6892):949-54 PMID: 12068308
  39. Gene methylation in thyroid tumorigenesis.
    Endocrinology. 2007 Mar;148(3):948-53 PMID: 16946009
  40. Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis.
    Cancer Res. 2003 May 1;63(9):2312-5 PMID: 12727855
  41. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
    Clin Cancer Res. 2007 Feb 15;13(4):1161-70 PMID: 17317825
  42. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee.
    Thyroid. 2004 Dec;14(12):1056-60 PMID: 15650358
  43. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
    J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 PMID: 16174717
  44. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3 PMID: 17488796
  45. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
    Brain Pathol. 2003 Oct;13(4):507-18 PMID: 14655756
  46. BRAF mutation in thyroid cancer.
    Endocr Relat Cancer. 2005 Jun;12(2):245-62 PMID: 15947100
  47. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.
    Cancer Res. 2003 May 1;63(9):2316-21 PMID: 12727856
  48. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes.
    Endocr Relat Cancer. 2006 Jun;13(2):485-95 PMID: 16728576
  49. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
    Cancer Res. 2005 May 15;65(10):4238-45 PMID: 15899815
  50. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    J Clin Endocrinol Metab. 2007 Jun;92(6):2264-71 PMID: 17374713
  51. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors.
    Eur J Endocrinol. 2001 Aug;145(2):129-35 PMID: 11454507
  52. Epigenetic therapy of cancer: past, present and future.
    Nat Rev Drug Discov. 2006 Jan;5(1):37-50 PMID: 16485345
  53. Thyroid nodules and cancer. When to wait and watch, when to refer.
    Postgrad Med. 2000 Jan;107(1):113-6, 119-20, 123-4 PMID: 10649669
  54. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies.
    J Clin Endocrinol Metab. 2004 Aug;89(8):3702-4 PMID: 15292292
  55. Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings.
    Ann Intern Med. 1984 Jul;101(1):25-8 PMID: 6547282
  56. Colorectal cancer: mutations in a signalling pathway.
    Nature. 2005 Aug 11;436(7052):792 PMID: 16094359
  57. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
    Oncogene. 2005 Oct 6;24(44):6646-56 PMID: 16007166
  58. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.
    Cell Cycle. 2007 Feb 1;6(3):377-9 PMID: 17297294
  59. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.
    Oncogene. 2006 Jul 13;25(30):4235-40 PMID: 16501605
  60. The block of thyroglobulin synthesis, which occurs upon transformation of rat thyroid epithelial cells, is at the transcriptional level and it is associated with methylation of the 5' flanking region of the gene.
    Exp Cell Res. 1989 Aug;183(2):277-83 PMID: 2767151
  61. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    J Pathol. 2004 Feb;202(2):247-51 PMID: 14743508
  62. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients.
    Am J Surg. 2003 Dec;186(6):702-9; discussion 709-10 PMID: 14672783
  63. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].
    Cancer. 1998 Dec 15;83(12):2638-48 PMID: 9874472
  64. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.
    Eur J Endocrinol. 2004 Mar;150(3):269-76 PMID: 15012610
  65. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein.
    Mol Endocrinol. 1998 Aug;12(8):1241-9 PMID: 9717849
  66. DNA methylation patterns and epigenetic memory.
    Genes Dev. 2002 Jan 1;16(1):6-21 PMID: 11782440
  67. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
    J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90 PMID: 17426084
  68. Tyrosine kinase mutations in human cancer.
    Curr Mol Med. 2007 Feb;7(1):77-84 PMID: 17311534
  69. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.
    J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57 PMID: 10404820
  70. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Int J Cancer. 2006 Nov 15;119(10):2322-9 PMID: 16858683
  71. PI3K/Akt signalling pathway and cancer.
    Cancer Treat Rev. 2004 Apr;30(2):193-204 PMID: 15023437
Article Info
Journal
Otolaryngologic clinics of North America
Abbr.
Otolaryngol Clin North Am
ISSN
0030-6665
DOI
10.1016/j.otc.2008.07.001
Email
mxing1@jhmi.edu
Published
2008-12-00
Pages
1135-46, ix
Language
English
Region
United States
NLM ID
0144042
PMCID
PMC2615411
Subset
IM
Grants
NCI NIH HHS · R01 CA113507 · United States
NCI NIH HHS · R01 CA113507-02 · United States
NCI NIH HHS · CA113507-01 · United States
External Links
PubMed source DOI: 10.1016/j.otc.2008.07.001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2